Document YG3KoZ27dkZR91V9oBqDDK7oy

DownloadRandom document
AR 226. 0663 N-EtFOSA Pharmacokinetic - [ 000475 | 2 WISCONSIN TORI8I ISSR NE Sponsor: 3M St. Paul, Minnesota + CORNING Coram, FINAL REPORT Study Title: Single-SDtousdey IonftrTa-v5e9n0o4usinPhRaarbmbaictoskinetic Author: Steven H. Glaza Study Completion Date: October 14, 1994 Ha33z0l1etoKninsWniasnconBsoiunl,evaIrndc. Madison, Wisconsin $3704 aboratory Project Identification: HWI 6329-117 Page | of 24 000476 Page 2 of 24 NI 6329-117 QUALITY ASSURANCE STATEMENT TWhiissconrseipno,rt Ihnacs. beiennacrceovrideawnecdebwyitthhethQeualFiotoyd AasndsurDarnucgeAdUaniitnisotfraHtaizolneto(n0A) GfoooldlowLianbgoraitnosrpyectPiroancsticweereRecgoulnadtuicotnesd,an2d1 CfFiRndi5n8g.s35re(pb)ort(e6d) t(o7).theThSetudy Dfiirndeicntgosr aarned miasnsaugeedmetnot.HazlWertiotntemnansatgaetmuesntrempoonrtthslyofacicnosrpdeicntgiontso asntdandard operating procedures. Inspection Dates Fron To _____ Phase 0033//0017//9944 0033//0071//9944 PBroodtyocWoelighRteview 0180//2161//9344 0180//2161//9944 DReaptoar/tRepRoer-tRevRieevwiew RepoDratteed to StudyDirector 0033//0072//9944 0140//2191//9944 Date tMoanagement 0064//1100//9944 0151//1100//9964 FRaenpcryeseDniteddtriivceh, Quality Assurance Unit Date [0-14-54 000477 Page 3 of 24 STUDY IDENTIFICATION Single-SDtousdey IonftrTa-v5e9n0o4usinPhRaarbmbaictoskinetic HHI 6329-117 Test Material Sponsor Sponsor's Representative Study Director Study Location StuEdxyperTiimmeenttaablleStart Date Experimental Termination Date 71-5904 T3Moxicology Services 2St2.0-2PaEu-l0,2 M3NM Ce55n1t4e4r J3oMhn L. Butenhoff, PhD T22o0x-i2cEo-l0o2gy3MSeCrevnitceers St. Paul, MN 55144 (612) 733-1962 HSatzelveentonM.WiGslcaoznasin, Inc. MPa.0d.isoBno,x 7545 WI 53707-7545 (608) 241-7292 HBuaizlldeitnogn NWoi.sco3nsin, Inc. M3a8d0i2soPna,ckWeIrs 5A3v7e0n4ue MMaarrcchh 97), 11999944 000478 MSSattnueadvgyeenrDi.recGtloarza Steven R. Sorenson Study Coordinator IPna-tTriifceiaSuPpaedrgvhiasnor RReopsoertM. `SBurpiedrgveisor Quality Assurance HShaenrgreyrR. W. Petsel Page 4 of 24 KEY PERSONNEL : HI 6329-117 SDCuiippneldorymvaiJts.eo,rCaAryL,LApN w AnatomicalPathology SDJeuabpcoekrravShiesrofL.rosrtP/irkel Necropsy PASanuntpeheorlvMoiogssyohreDrata 000479 Page 5 of 24 CONTENTS Quality Assurance Statement Study Identification Key Personnel Summary Objective Regulatory Compliance Test and Control Material Test System Procedures Results Discussion Signature Reference Table 1 Individual Body Weights (g) 2 Individual Clinical Signs AppPreontdoicxolA Deviations Protocol TP8084.PK HWI 6329-117 2Page 3 4 6 7 7 7 8 109 n11 1 12 13 11s 16 -_-- 000480 Page 6 of 24 HNI 6329-117 SumHARY aTdhimsinissttuedryedwasbydoinnetratvoenaosussessinjtehcetiloenveltoorfabsbyisttse.mic exposure of T-5304 when ff{aepcmnoeay/lgeernHoirucaph:)e.([NDZiOWmn)eStPDhFayy1r0a,Sbublitfthseoxiawdneeirmea(lDasHsSsOir)ge]nceeaditveaadt 10.0, 50.0, or 10 daroassneidnogvmlaeituomienftirovafeve0gn.ro5ousu.mpLs/ikngjeocrtio1 n0.of 0.0 ng of T-5904/kg of body weight. bf2Gre8aofinohnrioectuahrlestemsaoatfbrtsgmeeiarrntveairtniitaorlnasveandwomeuirsneiscitonrnjaedtcuitcoitonend.(DaatyBoa0dp)yp.rwoexiBiglmhoatotsdelywSearm0sp.l5,edset2,werrm4a,indc2'o4,lljeuasnnryded Sp{uo4rs8vt-i-hvoiiunnrjgsectapinooisnmt.a-lai.lnjIenecAatlra]idodvnsie)atiminopanlo,eTfsaratwgtheeertevhaoenclieumtnmaielmseofoaftble2o-x,opder4wi-am,sen6to,ablta1it2n-e,erdmianFnadetmi9o4nmabcehre Afneilmaaultsarsufrrvaicvtiinongs.to t`Thhee TheSshetized with sodium eanndinaolf tfhoeund48-dhetoarduirfdupugoresidtn-gainndtjheescetspitaourndaytpeewdraisiondmteeccarsceehmneenreannd pentobarbital and exsanguinated wit Tfhreozebnileto frthoem Sepaocnhsoarnimaafltersutrevrimviinnagtitoon toefrmtihneatiionn-1wiafse collechtoeudt phase. anegcroopes)y. dAdoodssueeinTilseevtverelasst,,ioahnnydpoofdaecTat-ti5hv9i0t4oyfrteihnseultahteneidnaanilinmatalrsedaetcterrdeeaatsateedtihnaet ft1oh0oed0.0c50o.mn0as./ukamgnpdtdiuoocneoatJnograd/l)lk"g 000481 Page 7 of 24 HI 6329-117 OBJECTIVE tThhee toebsjtecmtaitveerioafl,thiTs-59s0t4u,dywhweans to rabbits. atdomiansissetsseretdheasleavelsinogflesysitnetmriacveneoxupsosuirnejecttoion REGULATORY COMPLIANCE ATLdhamibisonriasstttourrdyaytiwSotanus'disceosGn,odoud2c1teLCdaFbRoirn5a8ta.ocrcyo"rAdPllarnaccpetrioccweeidtuhRreegtsuhleautsUei.doS.nsinFofotohdrisNaonndsctluDidrnyuigcsarle in Spcrpoeomvnpislooiurasncawenodrwkis.tthudHytahzedlierAtenocitnmoarlW,sisctWohenelsfiasnrteud(yHAHcItd)idRdeongeoustlatnuionotnnesca.cecsespaItrnilatynhyeduropeplsiipncoiaontnseiboiaflniytthye pfroersetnhteedanailnystihsisofreptohret.samples collected in this study nor are these results dentification TEST AND CONTROL MATERIAL TThhee St. cLtooeunsittsr,omlatMeimrsaistaoelurriiaw;laswLaoistdeNDnoit.mieft5ih3eyHdl06a3Ss4u;l1f-o5Exx9pi0.d4eMaan(rdOcMhSdOe)s4,cr(i1Sb9i9eg5dn)aaCasnhdeamidyceeasllclroiwCboemsdpoalniayds,. a clear, colorless Tiquid. Purity and Stability mdTaehteteerrSimpaiolnn/asvtoeirohniascslseu(mimeniscxlturuderisenpsgonfusonirdbeirclointtcyeesntftorcraotntideoisntt,iomnassto)el.urbiiallAitspyau,mrpilhteoymooagfnedntehsiettaytb.eisltsintdy rsetqaubeisltietdy supplier, dbaoyncaultmhyeesnetsSspownatsshoern.poturiTtthayekenCoferbtetihfefoircceoantatedrmooilfnimsaatntraelarytisiaiolsn, aosbttahiinsedwasFrownot as 99.9% Tne the psutrapboisleis'tyofofthtihse sctoundtyr.ol material was considered to be adequate for the Stoanrd Raetegntieon atTehcsectortdoeirsntgcoantntodroHclWoIntmraSottlearnidmaaalrtderwiiOalpllerawbteeirnedgisscPtarorordceededduartaeftre(orSoOPi)st.seumapnecreatuorfe.theAnfyinaulnusreedport 000482 Page 8 of 24 HMI 6329-117 Safety Precautions Tanhde tpoelsitciaensd. control material handling procedures were according to HHI SOPs TEST SYSTEM Test Animal AKdaullamtazaolob,inoHI,raobnbitFsebroufartyhe23r,a:1(9N9Z4W)aSnPdFmasitnrtaaiinnewdereatretcheeiHveadzleftroonm HWRiPs,conIsnicn., hfoaucsiilnigty`aattHH3I802comPpalckyerwsithAvesntuaen,darMdasdisoount,iinWeidscoinnsitnh.e "AGnuiimdael fohrusbthaendCrayreandand Ubsoettoomf LstaabionrlaetsosrysAteneilmalcsa"g.es iTnheteamnpiemraaltsurew-ereandindhiuvmiidduiatlyl-ycohnotursoeldledin qsucarreteenr-s, DpireotvidHeFd #a5c3c2e6s,s PtHoI waFeteedrs,adInlci.b,itaunmdahnedlda mfeoarsuarnedacacmloiumnattioonf pLearbioordatoofryatRabbit nTuetarsitti7ondaalys.Comp`Tohneenftesedanids renovuitrionnemleyntaanlalyczoendtambiynatnhtes.manSuafmapclteusreroffwoarter are wpaetreiroditchaatllwyoualndalhyazveed biyntHeMrIf.eredThweirtehweorreafnofecktneodwnthceonrteasmuilntasntsofitnhethestufdeye.d or Amlalintaaniinmaeldsduwreireng itdheentoibfsieerdvabtyioannimpaelriondumbaser spaencdifcioerdresfporondtiheng acecarlimtaagtioannd prearnigoedd. froDmur2i0ngtothe23cCondauncdttohef trheelatsitvuedy,humtihdeittyempraenrgaetdurefroomf 4t8hetoani6m0a%l. roThoem aninals were housed under the required temperature and humidity conditions. Selection of Test Animals Trheequiarneimmeanltss.were selected at random based on health and body weight Study Desian pFleancaelde ianntiomaltshewefioglhlionwigngfrosmtud2y,17g3routpos:2,386 g at initiation of treatment were Group Treatment Dos_(ema/Lkegvel Dosel/kVeo)lume ofNAunmibmearls 1 (Co2ntrol) 7-_O5M9S0O4 01.00 00.55 11 34 T7-15-9590044 5100..00 005s 11 5 T-5904 100.0 05 1 000483 Page of 24 HHI 6329-117 ification for Specis Selection cHhiositcoericbaelclayu,sethoef tNheew lZaeragleandamoWuhnitteofalbbiancokgrroaubnbditihnafsorbmeateinontheonantihmiasl spoefcies. PROCEDURES DPoserepaarndaAdtminiistoratnion fTohre etaecsht dmaotseerilaelvelw.as Adniluitneddiviwdiutahl DdHoSsOetoofaecahciheveresapescpteicviefictesctoncseonlturtiaotnionor ctornetartomlentw.as Tchaelcurleastpeedctifvoer etaecsht asnoilnuatlionbasweads oandmiintisstbeordeydwebiyghitntroanvetnhoeusday of (idnujreacttiioonn rianntgoinagmafrrgoimna3l5 teoar63veisne.condTsh)e. doTsheewapsrepgairveedn tasesta ssloolwutipounssh were rsetmoariendinagt treosotm tsoelmupteiroantsureweruentidliscaadrmdiendi.stered. After administration, any Reason for Route of Administration Intravenous injection is an acceptable route to assess systemic exposure. Observations of Animals Chloiunriscaalfteorbseirnvtartaivoennsouswerienjeccotnidounc.ted at approximately 0.5, 2, 4, 24 and 48 Body weights were determined just before test material administration (Day 0). sample Collections Boflooadll saanmipmlaelss (aatpp2r,ox4i,matanedly62homLu)rsweproest-cionljleeccttieodn.fromSubtsheequmeanrtgincaollleecatriovneinof Abtlootdhe ftrionme soufrvinveicnrgopsaynim(aalpsprwoaxsimactoenldyuct4e8d-hoautrs12 poansdt-i24njehcotuirosnp)osst-lairngjeectvioolnu.ne AoTf1 blsoaomdple(sapwperroexicmeantterliyfu4g5edtoan6d0 msle)pawraastedobtianitonedserfurnomanedachcelsluurlvairvinfgracatniiomanls:. TSphoensbolro.od samples were then stored frozen (-20C 10C) until shipped to the 000484 | Page 10 of 24 i Pathology HW 6329-117 Tnthheeecreoaxpnpismeyarliemxeafnmotiuannladtidpohenaasdea,nddusruiarnnvgyivtaihbnengorsamtnauildniyatliwseasswewsreuerbejeacnrteeecsdotrhdetetodi.zaendAatwbibtrtheevrimsaiotndeaidutmiognrososf psfreuonrztveoinbvairnbbgyitptalolactieannrgdmineianxtsiaaonngfuriwenaesazterecdolswleteictthteoodumtaainnndetcariiomnpmseyad.itaetmeTplhyeerapbtliualrceeedforfoonm -d7er0aycCh icae1n,0imCat.lhen After necropsy or bile collection, the animals were discarded. hi f Blood and Bil D5T.5h1e0J6ob)hlnosoaodfnt,esra3m4cpolmeEp.sEl.eatnid&onPb.ioCl.fe,wteBhelrdegi.ns-e12nit-f3efr-po0hz,aesne9.3(5onBudsrhy Aivceen)uet,o Stth.e PSapuoln,soMrN,(James Statistical Analyses No statistical analyses were required by the protocol. ocation of Raw Data, Records. and Final Report aTrhcehirvaewsdaotfa,ANIrecionrdasc,coradndancaecwoiptyhoHfHItheSOPf.inal report will be retained in the RESULTS Body Weights Individual and mean body weights are in Table 1. Clinical Observations a1In0ni.d0mi,avlidauntadrlea5t0ce.ld0inmiacgta/lk0g.0siamgpgnp/sekagraerdeexhniionbrmiTatalebdleata2.0de.c5rTehaaensdea2niinmhaoulfrsosodtprcoeosantts-euidnmjpaettcito0in.o0n,a.t 14.,0T,he24, taIhnnedf4o48o8-dhhocouuorrnss.uobmspetTrihvoeantaianotinm.a4lsaTnhdter2e4aantiehmodaulrast,tr1et.ah0teneadndraett1u0r5.n00e.d0mgm/tako/gkagexneohrximhbaiilbtietdaepdpaeadreacnrceeaseat 7ha.ny5dpoh4a8ocutrihsvouirtpsyo.sta-tiTnh4jeeacantndiiom2an4l hfootlurlreosawtieandngdastaigd1ne0sc0.r0eofamsahe/ykpigonacwftaoisovdiftcoyuonnds(uatdmepat2dioannadppart4oxh4,oiumra2s4t),ely and decreased food consumption (at 4 hours). 000485 Page 11 of 24 HHI 6329-117 | pathology oTfhethaenimeaxlpseritmreenattaeld apthas0.e0,and1.w0,ere10.n0o,t naencdro5p0s.i0edm.g/kTghesuarnviimvaeld ttroeatteerdminatation v1i0s0ibnlge/kglesdiioendsoninthtehisdayaniomfalt.reatment and was necropsied. There were no DISCUSSION Trahbebiltesvelwheonf saydsmtienmiisctereexdposasurea soifngTl-e590i4ntrwaasveneovuasluaitnejdectiinonfeamtalelevaellbsinoof 0.0, t1h.0i,s m1a0t.e0,ria5l0.0r,esualntded100i.n0amdge/ckrgeausseinginDHfSoOodascontsheumpvteihiocnlea.t alAldmidnoissetrlaetvielosn, of htryepaotaecdtivaittytheat10t0h.e05m0g./0kganddos1e00l.e0venlg./kg dose levels, and death of the animal SIGNATURE SSttuedvyenDiW.recGtloarza Acute Toxicology Date 14-04 REFERENCE 1. NIH Publication No. 86-23 (revised 1985). 000486 Page 12 of 24 Individual TaBboldey 1 Weights (g) LeDovseel Animal Group (mo/ka) Sex Number Day0 1 0.0 Female F50169 2,231 2 1.0 Female FS0170 2,386 3 10.0 Female F50171 2,176 4 50.0 Female F50097 2,173 H 100.0 Female F50098 2,300 HHI 6329-117 000487 Page 13 of 24 Table 2 Individual Clinical Signs HWI 6329-117 Grow L(neDoov/sekela) Sex AnMimmbaelr Observation GF 2Hd ow ZI 1 0.0 Female FS0169 ADepcpreeaarseeddnfoomoadl 4s. . consumption = =, 4 consumption. yy. 2 1.0 Female F50170 Appeared normal 4 4 - - 4 Decreased food 3 10.0 Female F50171 ADepccpreoeaarnseedsd nuofrommoadpl tiJov n.J - , - , 4 4 0.0 Female F50097 HyAppopaeacrteidvimtoymal +E4A... Deccroenassuemdptifoonod ~~, yy 5 100.0 Female F50098 Appeared normal 7 - - Hypoactivity - /J Decreased food Fouc(no=d7n.s5udemahpdotuirosn - - J post-injection) - - / Indicates condition exists. = Not applicable. 000488 Page 14 of 24 APPENDIX A Protocol Deviations Protocol TP8084.PK HWI 6329-117 000489 Page 15 of 24 Protocol Deviations HI 6329-117 Protocol CP.agDeos6,ing7. PrEoxcpeedruirmeesn,tal(1)Design, DionsjiencgtioRnoutien.to aInmtarragviennaolusear 3v0einsecoovnedrs.approximately Actua) Procedure fThreonr3a5tetoof63insjeeccotnidosn. ranged DP.agOebs7,erv7a.tiEoxnperoifmeAnnitmaallsD,esi(g3n), oSfampCloelleCcotliloenc.tionBsl,ood(c)samMpeltehsod t(h2emm)argwiinlall beearcovlelienc.tedInfrom nadedcirtoiposny, apatprotxhiemattiemleyof50 f7r0onmLeaocfhblanoiomdalw.ill be obtained bAlosoedpawraasteno2t-nLtakseanmplaet tohfe (t4i8mehooufrstheposstc-hiendjuelcetisoanc)rifice psoisnscieblaes m(uacphprobxliomodatevloylu4m5e taos 6a0nimnall). was obtained from each EP.ageTer8,min7a.tiEoxnp,eri(m2e)ntSaclhedDuelsiegn, CSoalclreicftiicoen,. (a)Thesabmipllee from each wainlilnalbe scuorlvlievcitnegd toandtermination tihmemnedifarotzeelny bpylacpeladcionngdriyn aice tfermepeezerratusreet otfo m-a2i0nCtai1n0aC. Tinneabiflreeezsearmplseest wteoremaipnltaaciend a temperature of -70C 10C. oTuhtecsoenedeovfiatthieonsstuadrye. not considered to have had an adverse effect on the 000490 ! R RAA SEE O NLSR N Page 16 of 24 Comm mtr Sponsor: St. Paul,mnMinnesota PROTOCOL Teg084..pK Stugy Title: Single-Dose Intravenous Pharmacokinetic Study of T-5904 in Rabbits Date: March 4, 1994 MHa3ad3zi0ls1eotnKo,innWsWimisascncoonnBssoiiunnl,ev5aI3rn7dc0.4 LaboratoryProject Identification: WE 6329-117 Or IS ne en sussunnn wn a LT 000491 Page 17 of 24 - STUDY IDENTIFICATION Single-Dose IonftrTa-v5e9n0o4usinPhRaarbmbaictoskinetic Study HHI No. Test Material Sponsor Sponsors Representative Study Director Study Location ProEpxpoesreidmeSnttuadly Timetable Start Date Experimental Draft Report Termination Date Date 6329-117 T-5904 TMomxicology Services S1t2.20-P2a6u-l0,2 H3NM Ce5n51t4e4r J3Hohn L. Butenhoff, PhD T22o0x-i2co-l0o2gy3HSeCrevincteesr S(t6.12)Pau7l3,3-1H9N62 55144 HSatzelveetnonM. WiGslcaoznasin, Inc. MPa.d0i.soBno,x 7545 WI 53707-7545 (608) 241-7292 HBuaizlldeitnogn WNoi.sco3nsin, Inc. M3a8d0i2soPna,ckWeIrs A53v7e0n4ue WWeeeekk ooff MMaarrcchh 77,, 11999944 Week of April 11, 1994 PPa8ge082 4P.K 000492 Page 18 of 24 PTa8ge0834P.K 4. SSitnugyle-Dose Intravenous Pharmacokinetic Study in Rabbits 2. piTtourpaissosseaesdsaintihestelreevedlasofassyisntgelmeicienxtproavseunroeustointjheecttieosnt mtoatecruisamlitwhen 3. ReTahiuslasttourdyyCwoimlpllibaencceonducted in accordance wi,th the following Good Laboratory Practice Regulations/Standards/Guiindees): [{xC]o2n1duCFcRt83s(2FAH)onregulated Study [{1] 1 {1 4400 CCFFRR 716502" ((epPAA--TFsICFAR)A) C(81)30 (Final) (OECD) [] [1] Notification Notification Ko. No. 331835,0, MaArucghust31,10,198129,84an(dJaapsaneasmeendHeAdFF)by Notification No. 870, October 5, 1988 (Japanese MOHW) WAeIlfaprreocAecdtureRseguilnattihoinss.protioncotlhe aorpeiniinoncoomfplitahenceSpownitshor taheedAnmiommaa]y director, the study does work. Hazleton does not not unnecessarily duplicate accept any responsibility any previous roefsutlhtes sbaemplperseseonrtetdissinuesthecolrleepocrttedofinthtihsisstsutduyd.y for the nor will analysis these 4. Quality Assurance Tthhee Qpuraoltoictoyl,AsssutruadnyceconUdnuictt,in anadccotrhdeanfcienalwitrhepHoarztlewtiloln bbersaumdoittceed by 5. Test Material (HWI) Standard Operating Procedures (SOPs) and policies. A. = Identification 8. PhVyelsoicwalsaDletsdcription C. Purity and Stability dTehteerSmpionnastoironasssu(miensclurdeisnpgonusnidbeirlittyestfocronpduirtiitoynsa)n.d s*taSbaimlietcyof ctoensctenmtartaetriioanl,/veshoilcublielimtiyx,turheo(mso)gen(eiiftya,ppalnidcabsltea)bi]fostry analyses WSapifoltnlesrobree.xptearTkihemenesnebteafsloamrpetleerasmdimn(iaintfiisottnarkaetfnio)ronpwoiislfslirbbeleeq.uesessntpteedltsobsyitshteheSponsor 0. Rsotoomragteemperature 000493 Page 19 of 24 TPaPg8e0484P.K CE. RReesseerrvvee Ssaammplleess will not be required for this study. F. Retention tAhney fuinnuasledretpeosrtt,matuenrlieasls dwiilrlectbeeddoitshcearrwdiesde abfytertheisSspueanncceer.of 6. SaAsferteyqupirreecdaubtyioHnIs SOs and policies 6. Vehicle A Identification Dimethyl Sulfoxide (DMSO); report. date to be recorded in the Lot number, source, and expiration data file and included in the final 8. Ph(yTsoibcealdoDceusmcernitpetdioinn the raw data) C. puarndiStatbilyity To be documented by HWI (information from the supplier). D. SRtooornagteemperature E. SReeeserSevcetiSoanm,pl5e.s E. Reserve Samples F. ARneytenrteimaoinning Final report: vehicle will be discarded after issuance of the 6. SaAsferteyquPirreecdaubtyioHnIs SOPs and policies 7. Experinenta)Desian A. Animals (1) SRpaebcbiites @) sHtraii(NnD/Wrs)oSuParFcHeR:P, Inc. 3) AsIenaittiation Adult (4) sZeloahtt 3at0kInitiation 000494 Page 20 of 24 - (5) 5Numfebmearleasnd Sex PTapgae0845 PK (6) InIddeinvtiidfuiaclatniuonmbered ear tag (7) Husbandry a) Housing A Individually, (heavy gauge) in screen-bottom stainless steel cages (b) AF(oPmoHIdeasFeuerdesd, anIoncu.n)t. ofAnLiambaolrsatwoirlyl RnaobtbitbeDifeatsteHdF b#e5t3o2r6e ebdynosveithreaodmmmeainnntuiasfltarcacttouinrotenar.mifnoarTnhtnesu.tfroiotdioinsalrocuotmipnoenleyntasnatlaygzed (c) M4adteTribitua from an automatic system. Samples of the water are hardness, aanndalsyzpeedcifbiyedHWmIicfroorbitooltoaglicdailsscoolnvtedentsolaindds, for selected elements, heavymetals, organophosphates, and chlorinatedhydrocarbons. (d) CThoenrteamairneanntos known contaminants in the food or water that would interfere with this study. (e) EEnnvviirroonnmmeennttal controls for the animal room will be rseetlattiovemahiuntnaiidnitya otfem5p0e%ra2tu0r%e, of`an1d9a to122-3hoCu,r a Vight/12-hour dark cycle. (f) AActclTiemaasttio7ndays (8) SeleofcTetstiAnoinanls Based on adequate health number and body of extra weight animals according to HWI SOPs. will be purchased so An that no animal in obviously poor health is placed on test. (9) Justification for Species Selection bHtahicesktgoarrnoiicumaanlldlyoi,fnfcothrhomeiatcNieeownbeZcoenaaultsahneidsofWshipttheeecilaealsrbgienoamroaubnbtitohfas been 0004395 Page 21 of 24 B. Dose Administration PPa8ge084P.K . (1) Iest Groups Group DoseLevel Ama/ka) Number of [Females 1 0 (Control) 1 452 105010..000 5 100.0 i11 1 a wTehieghdtose volume will be 0.5 mL/kg of body C. DosingProcedures (1) DoIsntirnagveRnoouusteinjection into a marginal ear vein over approximately 30 seconds. (2) R sIynsttre eanviefcnoa oruesDxpos oissniujnreo gec.tRioon unt1es an acceptable route to assess (3) DoSsinignlge udorsaetion (4) DoPT(hDsreHeSeDTp)easttroamaattciehrioienavle Tevel. Individual dwaoislslepsecbwieiflidlcilbcueotneccdaelnwctiurtlahattideoidmnetbfhaoysxledeascouhnlfgtohaxeri.ede animal's body weight taken just before test material gtaredommuippnesir.sattruTarhteeioupnn.rteiplarTeahddemitdneoissstetrmvaiotxlituoumnre.eswiAwlilfltlebrebeaeqdusmatilonriebsdettrwaateteinroonoamll any remaining test mixtures will be discarded. 0. ObservoafAtniimoalns (1) ClinicalObservations - after treatnent. The animals toxicity at waiplplroxbiemaotbesleyrve0.d5,for2.0c,lin4i.0c,al 24s,ignasndo4f8 hours (2) Body Meights Just before test material administration. Be ---- 000496 ' Page 22 of 24 (3) Sample Collections PPa8ge0874P.K (2) E2r,e4q,uen6c,y8, 12, 24, and 48 hours post-injection (b) aMunsber of Animals (c) BMleotohdodsaomfplCeoslle(2ctailo)n will be collected fron the mnaercgrionpasly, caarppvreoixni.mateIlnya5d0dit-io7n0,'nLatofthbelotoidnewiolfl be obtained from each animal. The samples will be tshteoresdepaartatreoomsertuenmpaenrdatucreellualndarthfernactcieonntsrifsutgoerde,d aatnd e=fx1rp0aecrCtiinotenonst-aw3li0llCt.erbemiTnshaeetnitsoenpfarforozaretnedpotsosseitrbhuleme Safnpduotnuscroeerllualfatrer analysis. Samples will be shipped to: BMJladmEge.sE3D.-3E6JP-oC0h9n.son 935 Bush Avenue St. Paul, MN 55106 James 0. Johnson will be notified by telephone at (612) 778-5294 prior to the shipment of the samples. E. Termination (1) UnscheduledSacrifices and Deaths mAnoriabbubnrdevicaotndeidtigornosswilnlecrbeopsayneswitlhletibzeeddonwei.th Asnoidmiaulms in a pentobarbital and exsanguinated without necropsy. (2) ScheduledSacrifice At approximately 48 hours post-injection, animals will be waintehsotuhtetinzeecrdopwsiyt.h sodium pentobarbital and exsanguinated 000497 Page 23 of 24 PPa8ge0884P.K - (a) Sample Collection wTihlel bibelecoflrloencteeadchanadnimiamlmesdiuartveilvyinpglatcoedteornmidnraytioince ttehmepnerfartouzreen obfy p-2l0acCing10inC.a freezer set to maintain a eTxhpeerbiimleent(aflrozteenr)miwnialtlionbefsorentpososnibdlrey samples will be shipped to the person fiucteurteo listed tanhaelySspiosn.sorThaefter in Section 7.0.3).(0). F. SNotatsitsattiicsatlicaAlnalaynasleysses are required. 8. ARepfoinratl report including those items listed below will be submitted. DDeessccrriippttiioonn ooff tthhee tteesstt smaytsetreimal DPartoecsedoufresexperimental initiation and termination Description of any toxic effects 9. LOforacicgaiitlniiaotlnateodaftaauR,daiwtoirDantgcao,tphieeRsecsottruhddesyr,eodfua,rndinwgiFlilniatlsbepRraeovpgaorireltsasbleandatbHeHfIoreto raalecltcaeiopnrteiadgnicneianloftpheatpheearrcfhdiiantvalae,s reoipfnocrHltWu.IdinagcWchoetrnhdoistnehgeitftoienmaHlWlIisrSteOepPdo.rtbelioswcwoimlplletbeed, DPorsoetocporlepaarnadtipornotorceoclordasmendments InB-oldifyeweriegchotrsds DOobsseervaadtmiionnisstration SStaumdpylecocrorlelsepcotnidoenncreecords Final report (original signed copy) The not bfeolalrocwhiinvgedsuwpiptohrttihneg rsetcuodrydsdatwai.ll be retained at WWI but will WAnaitmearl anraelcyesiipst/arceccloirmdsation records ARneifmrailgerraotoomr taenmdperfarteuerzeerantdemhpuemriadtiutrye rreeccoorrddss Instrument calibration and maintenance records 000498 Page 24 of 24 PROTOCOL APPROVAL TPoaegoes'es px edBtd Joh L." Butenhoff, PhD shSponsor's Representative IW.L craze NW Study Director Acute Toxicology Hazleton Wisconsin, Inc. Cor esLeendtitive HQauzalleittoynAWsissucroannscien,Unintc. (6329-117.PK,dsk2) ancl 7, 974 Date Bp ate ea Tate ogJos - A-- . 1 SY000499 |